Clinical and experimental dermatology · 2025
Efficacy and safety of topical methotrexate gel 1% in combination with microneedling vs. cryotherapy for the treatment of cutaneous warts: a prospective randomized controlled trial.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hofny Eman Riad Mohamed, Alhakami Khulood Fadhl, Abouelmagd Sara A, Hassan Sara A, Fathy Eman, Hassan Heba
Аннотация
BACKGROUND: Cutaneous warts continue to represent a therapeutic challenge because of treatment resistance and the inconvenience of most modalities of treatment. Topical methotrexate (MTX) with improved delivery methods may be a viable tool for certain localized dermatological conditions. Regarding cutaneous warts, MTX, either topical or intralesional, is one of the promising lines of treatment.
OBJECTIVES: To investigate the efficacy and safety of topical MTX hydrogel 1% combined with microneedling in the treatment of cutaneous warts compared with traditional cryotherapy.
METHODS: Sixty-eight patients with common or plantar warts were enrolled in this study. Patients were divided randomly into two groups: group A, which included 34 patients who received topical MTX hydrogel 1% combined with microneedling, and group B, which included 34 patients who received cryotherapy. All patients were followed up for 3 months after finishing treatment to detect any recurrence.
RESULTS: Regarding size after treatment, the complete resolution of warts was higher in group B (65%, 22/34) than in group A (53%, 18/34). The difference between both groups in clinical response did not reach statistical significance. There was no statistically significant difference between groups A and B regarding pain and erythema (P = 0.28 and P = 0.51, respectively). The rates of blistering and hypopigmentation were significantly higher in group B than in group A (P < 0.001 and P < 0.05, respectively). During the 3-month follow-up period, no recurrence was found in either group.
CONCLUSIONS: Topical MTX hydrogel 1% combined with microneedling is an effective and safe therapeutic option in the treatment of common and plantar warts.
OBJECTIVES: To investigate the efficacy and safety of topical MTX hydrogel 1% combined with microneedling in the treatment of cutaneous warts compared with traditional cryotherapy.
METHODS: Sixty-eight patients with common or plantar warts were enrolled in this study. Patients were divided randomly into two groups: group A, which included 34 patients who received topical MTX hydrogel 1% combined with microneedling, and group B, which included 34 patients who received cryotherapy. All patients were followed up for 3 months after finishing treatment to detect any recurrence.
RESULTS: Regarding size after treatment, the complete resolution of warts was higher in group B (65%, 22/34) than in group A (53%, 18/34). The difference between both groups in clinical response did not reach statistical significance. There was no statistically significant difference between groups A and B regarding pain and erythema (P = 0.28 and P = 0.51, respectively). The rates of blistering and hypopigmentation were significantly higher in group B than in group A (P < 0.001 and P < 0.05, respectively). During the 3-month follow-up period, no recurrence was found in either group.
CONCLUSIONS: Topical MTX hydrogel 1% combined with microneedling is an effective and safe therapeutic option in the treatment of common and plantar warts.